EUVIMEDEUVIMED entdecken
Open Access

AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma

Cheng Gao, Liang Chang, Tianxin Xu, Xiaojun Li, Zhong Chen

Journal of Gastrointestinal Oncology · 2023-06 · 14 (3) · 1412-1433

DOI: 10.21037/jgo-23-277 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal Oncology, 2023-06. Verfasst von Cheng Gao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Aldo-keto reductase family 1 member C1 (AKR1C1)biomarkerdrug sensitivityhepatocellular carcinoma (HCC)lenvatinib resistance

Autor:innen und Institutionen

  • Department of General Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
  • Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, China.

Zitieren

APA

Gao, C., Chang, L., Xu, T., Li, X., & Chen, Z. (2023). AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 14(3), 1412-1433. https://doi.org/10.21037/jgo-23-277

Vancouver

Gao C, Chang L, Xu T, Li X, Chen Z. AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma. Journal of Gastrointestinal Oncology. 2023;14(3):1412-1433. doi:10.21037/jgo-23-277

BibTeX
@article{Gao2023,
  author = {Gao, Cheng and Chang, Liang and Xu, Tianxin and Li, Xiaojun and Chen, Zhong},
  title = {AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma},
  journal = {Journal of Gastrointestinal Oncology},
  year = {2023},
  volume = {14},
  number = {3},
  pages = {1412--1433},
  doi = {10.21037/jgo-23-277}
}
Kostenlos starten →